VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Ongoing trials in AML and HR-MDS: ENHANCE, ENHANCE-2 and ENHANCE-3

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses three ongoing studies investigating various treatment combinations in acute myeloid leukemia (AML) and high-risk (HR) myelodysplastic syndromes (MDS), including the ENHANCE study (NCT04313881), the ENHANCE-2 study (NCT04778397), and the ENHANCE-3 study (NCT05079230). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter